70% Had Knee Pain Halved in Weight-Loss Drug Trials
70% Had Knee Pain Halved in Weight-Loss Drug Trials
70% Had Knee Pain Halved in Weight-Loss Drug Trials
Key points
اہم نکات
मुख्य बातें
- Nearly 70% of patients on retatrutide saw their knee pain cut at least in half in two major trials published November 8 in the New England Journal of Medicine.
- The experimental weekly injection from Eli Lilly was tested in 1,019 adults with obesity and knee osteoarthritis across two phase 3 trials, TRIUMPH-4 and TRIUMPH-1-OA, where patients lost 17% to 25% of their body weight against about 4% on placebo, and pain fell by roughly 4 points on a 10-point scale compared with about 2 on placebo.
- The drug, which targets three hormone receptors, is not yet approved by regulators, and the trials did not show whether it repairs cartilage or slows arthritis itself.
- Nearly 70% of patients on retatrutide saw their knee pain cut at least in half in two major trials published November 8 in the New England Journal of Medicine.
- The experimental weekly injection from Eli Lilly was tested in 1,019 adults with obesity and knee osteoarthritis across two phase 3 trials, TRIUMPH-4 and TRIUMPH-1-OA, where patients lost 17% to 25% of their body weight against about 4% on placebo, and pain fell by roughly 4 points on a 10-point scale compared with about 2 on placebo.
- The drug, which targets three hormone receptors, is not yet approved by regulators, and the trials did not show whether it repairs cartilage or slows arthritis itself.
- Nearly 70% of patients on retatrutide saw their knee pain cut at least in half in two major trials published November 8 in the New England Journal of Medicine.
- The experimental weekly injection from Eli Lilly was tested in 1,019 adults with obesity and knee osteoarthritis across two phase 3 trials, TRIUMPH-4 and TRIUMPH-1-OA, where patients lost 17% to 25% of their body weight against about 4% on placebo, and pain fell by roughly 4 points on a 10-point scale compared with about 2 on placebo.
- The drug, which targets three hormone receptors, is not yet approved by regulators, and the trials did not show whether it repairs cartilage or slows arthritis itself.
Nearly 70% of patients on retatrutide saw their knee pain cut at least in half in two major trials published November 8 in the New England Journal of Medicine. The experimental weekly injection from Eli Lilly was tested in 1,019 adults with obesity and knee osteoarthritis across two phase 3 trials, TRIUMPH-4 and TRIUMPH-1-OA, where patients lost 17% to 25% of their body weight against about 4% on placebo, and pain fell by roughly 4 points on a 10-point scale compared with about 2 on placebo. The drug, which targets three hormone receptors, is not yet approved by regulators, and the trials did not show whether it repairs cartilage or slows arthritis itself.
Nearly 70% of patients on retatrutide saw their knee pain cut at least in half in two major trials published November 8 in the New England Journal of Medicine. The experimental weekly injection from Eli Lilly was tested in 1,019 adults with obesity and knee osteoarthritis across two phase 3 trials, TRIUMPH-4 and TRIUMPH-1-OA, where patients lost 17% to 25% of their body weight against about 4% on placebo, and pain fell by roughly 4 points on a 10-point scale compared with about 2 on placebo. The drug, which targets three hormone receptors, is not yet approved by regulators, and the trials did not show whether it repairs cartilage or slows arthritis itself.
Nearly 70% of patients on retatrutide saw their knee pain cut at least in half in two major trials published November 8 in the New England Journal of Medicine. The experimental weekly injection from Eli Lilly was tested in 1,019 adults with obesity and knee osteoarthritis across two phase 3 trials, TRIUMPH-4 and TRIUMPH-1-OA, where patients lost 17% to 25% of their body weight against about 4% on placebo, and pain fell by roughly 4 points on a 10-point scale compared with about 2 on placebo. The drug, which targets three hormone receptors, is not yet approved by regulators, and the trials did not show whether it repairs cartilage or slows arthritis itself.
Most read
سب سے زیادہ پڑھی گئی
सबसे ज़्यादा पढ़ी गई
- Loading...
Get news in your inbox
خبریں اپنے ان باکس میں حاصل کریں
खबरें अपने इनबॉक्स में पाएं
One email when new stories are published. No spam, unsubscribe anytime.
نئی خبریں شائع ہونے پر ایک ای میل۔ کوئی سپیم نہیں، کسی بھی وقت ان سبسکرائب کریں۔
नई खबरें प्रकाशित होने पर एक ईमेल। कोई स्पैम नहीं, कभी भी अनसब्सक्राइब करें।